|Bid||0.00 x 900|
|Ask||90.00 x 1200|
|Day's range||74.51 - 74.94|
|52-week range||58.81 - 75.62|
|PE ratio (TTM)||49.92|
|Earnings date||26 Jul 2018|
|Forward dividend & yield||0.76 (1.02%)|
|1y target est||78.86|
Baxter's (BAX) Q2 earnings likely to be aided by promising international ventures and acquisitions; cyclophosphamide competition raises concern.
Stryker (SYK) and Baxter's (BAX) strong expected growth rates and rising share price make them close contenders in the MedTech industry.
I am going to run you through how I calculated the intrinsic value of Baxter International Inc (NYSE:BAX) by taking the expected future cash flows and discounting them to today’sRead More...
After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).
Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA
Boston Scientific’s (BSX) enterprise value is $45.1 billion, and its enterprise-value-to-revenue ratio is 4.98x. The stock is trading at a forward PE multiple of 21.86x, which is expected to have a five-year growth multiple of 2.13x. Its price-to-sales ratio is 5.23x, and its price-to-book ratio is 6.72x. Its enterprise-value-to-EBITDA ratio is 18.5x.
Baxter International Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for BAX for clues.
Baxter International (BAX) has been regularly carrying out stock repurchases, a positive sign for investors. Baxter International generated $447 million from operating activities in the first quarter of 2018 compared to $206 million in Q1 2017. Baxter’s days payable outstanding increased from 48.6 days in Q1 2017 to 57.8 days in Q1 2018.
Baxter International (BAX) generated net sales of $2.7 billion in the first quarter of 2018 compared to $2.5 billion in Q1 2017. Baxter’s gross margins were affected by a negative impact from foreign exchange rates and the impact of lost sales due to Hurricane Maria and incremental supply chain costs in the first quarter. The company’s gross profit increased marginally from $1 billion in Q1 2017 to $1.1 billion in Q1 2018.
Sales from Baxter International’s (BAX) Acute Therapies rose 22%, from $106 million in Q1 2017 to $129 million in Q1 2018 on the back of higher demand for Baxter’s CRRT (continuous renal replacement therapies) systems. In July 2017, Baxter International acquired Claris Lifesciences’ subsidiary Claris Injectables for a cash consideration of $629 million. Through this acquisition, Baxter gained capabilities in the production of essential generic injectable medicines such as anesthesia and analgesics, renal, anti-infectives, and critical care in bags, vials, and ampoules.
Baxter generates a major part of its revenues from the Americas segment, which contributed $1.44 billion to the company’s total revenues in the first quarter, from $1.37 billion in Q1 2017. The company generated $724 million of revenue from its EMEA segment in the first quarter of 2018 compared to $631 million in the first quarter of 2017.
Baxter International’s (BAX) global business units include the following: Renal Care: peritoneal dialysis and hemodialysis therapies Medication Delivery: intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices Pharmaceuticals: premixed and oncology drug platforms, inhaled anesthesia, critical care products, and pharmacy compounding services Nutrition: parenteral nutrition therapies Advanced Surgery: biological products, medical devices used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention Acute Therapies and Other: continuous ...
Baxter International (BAX) provides a broad portfolio of essential healthcare products. Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating. Six have given it a “hold,” and one has given it a “sell.” The mean rating for the stock is 2.3 with a target price of $78.33, implying an upside potential of 4.1% over the stock’s closing price of $75.28 on June 5.
Strategic buyouts consistently help Baxter (BAX) gain market traction. Recently, the company completes the consolidation of both RECOTHROM and PREVELEAK.
Intuitive Surgical (ISRG) looks to install a broader base of its flagship da Vinci surgical system through distributor Vattikuti in India.
The medical device lobby is extremely apprehensive on proposed tariffs on Chinese products as these could significantly affect international trade.